NightHawk Biosciences Inc (NHWK)

[Paraceratherium]

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Heat Biologics with an Overweight rating and $22 price target. Recent positive data in the company's lead program, HS-110, highlight the strength of the company's proprietary immunotherapy platforms, said Kluska, who believes that "investors have yet to fully appreciate the potential utility of both this dataset and the versatility that Heat's platforms." Given where the stock is currently trading, she sees "significant upside" for HS-110 in NSCLC alone, but she also sees potential for expanded applications across solid tumors and COVID-19 for the company's other assets, the analyst added.

From Tradelike1 on stocktwits.

Note: $50 is still the price target regardless what Kristen Kluska says :)